HLB Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2019	FY 2018	FY 2017
Period Ending	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Revenue	36,100	20,541	15,558
Revenue Growth (YoY)	75.75%	32.03%	-
Cost of Revenue	18,058	16,075	12,797
Gross Profit	18,042	4,465	2,760
Selling, General & Admin	13,672	7,281	3,417
Research & Development	1,870	2,474	2,736
Amortization of Goodwill & Intangibles	69.49	59.69	117.71
Other Operating Expenses	197.98	246.97	155.02
Operating Expenses	16,601	10,292	6,613
Operating Income	1,441	-5,826	-3,853
Interest Expense	-1,192	-859.58	-2,107
Interest & Investment Income	36.96	392.45	531.35
Currency Exchange Gain (Loss)	1.79	-5.17	-76.26
Other Non Operating Income (Expenses)	-90.42	447.16	828.7
EBT Excluding Unusual Items	196.89	-5,851	-4,676
Gain (Loss) on Sale of Investments	120.89	164.96	-332.17
Gain (Loss) on Sale of Assets	-2.08	-31.53	-45.09
Asset Writedown	-438.73	-	-509.63
Pretax Income	-123.03	-5,718	-5,563
Income Tax Expense	-595.69	1,342	-116.36
Net Income	472.66	-7,060	-5,447
Net Income to Common	472.66	-7,060	-5,447
Shares Outstanding (Basic)	14	14	12
Shares Outstanding (Diluted)	14	14	12
Shares Change (YoY)	2.30%	13.08%	-
EPS (Basic)	34.13	-521.49	-455.00
EPS (Diluted)	34.13	-521.49	-455.00
Free Cash Flow	-43.8	-2,872	-3,020
Free Cash Flow Per Share	-3.16	-212.19	-252.31
Gross Margin	49.98%	21.74%	17.74%
Operating Margin	3.99%	-28.37%	-24.77%
Profit Margin	1.31%	-34.37%	-35.01%
Free Cash Flow Margin	-0.12%	-13.98%	-19.41%
EBITDA	3,081	-4,684	-2,798
EBITDA Margin	8.53%	-22.80%	-17.98%
D&A For EBITDA	1,640	1,143	1,055
EBIT	1,441	-5,826	-3,853
EBIT Margin	3.99%	-28.36%	-24.77%
Advertising Expenses	63.27	81.18	98.91

Source: S&P Global Market Intelligence. Standard template. Financial Sources.